A carregar...
Immune Checkpoint Inhibition in Oesophago-Gastric Carcinoma
Immune checkpoint inhibitors enrich the therapeutic landscape in oesophago-gastric carcinoma. With regard to oesophageal squamous cell carcinoma (ESCC), the selective PD-1 (programmed cell death receptor 1)-inhibitor nivolumab improves disease-free survival in the adjuvant therapy setting (CHECKMATE...
Na minha lista:
| Publicado no: | Pharmaceuticals (Basel) |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7918118/ https://ncbi.nlm.nih.gov/pubmed/33673374 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph14020151 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|